300683 Stock Overview
A biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Wuhan Hiteck Biological Pharma Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥24.34 |
| 52 Week High | CN¥36.19 |
| 52 Week Low | CN¥18.80 |
| Beta | -0.35 |
| 1 Month Change | -8.32% |
| 3 Month Change | 14.81% |
| 1 Year Change | -28.41% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -34.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300683 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -6.0% | -3.0% | -2.1% |
| 1Y | -28.4% | -19.0% | 9.8% |
Return vs Industry: 300683 underperformed the CN Biotechs industry which returned -19% over the past year.
Return vs Market: 300683 underperformed the CN Market which returned 9.8% over the past year.
Price Volatility
| 300683 volatility | |
|---|---|
| 300683 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 300683 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300683's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,520 | Ya Chen | www.hiteck.com.cn |
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products includes Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; indometacin and furazolidone suppositories for internal and external hemorrhoids, anal swelling, fistula, and other anorectal diseases; tinidazole suppositories for trichomonas vaginitis and bacterial vaginosis; nimodipine sustained release tablets for ischemic cerebrovascular disease, migraine, and cerebral vasospasm; trimetazidine dihydrochloride tablets for treatment of stable angina; and azithromycin granules for treatment of acute pharyngitis, tonsillitis, and bronchitis. The company also provides measles and rubella virus nucleic acid detection kit; isolation and identification tube and kit for mycoplasma; and bacterial vaginosis (BV) rapid test kit, as well as diagnostic kit for novel coronavirus N-Protein.
Wuhan Hiteck Biological Pharma Co.,Ltd Fundamentals Summary
| 300683 fundamental statistics | |
|---|---|
| Market cap | CN¥3.19b |
| Earnings (TTM) | -CN¥134.13m |
| Revenue (TTM) | CN¥614.85m |
5.2x
P/S Ratio-23.8x
P/E RatioIs 300683 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300683 income statement (TTM) | |
|---|---|
| Revenue | CN¥614.85m |
| Cost of Revenue | CN¥371.97m |
| Gross Profit | CN¥242.88m |
| Other Expenses | CN¥377.01m |
| Earnings | -CN¥134.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 39.50% |
| Net Profit Margin | -21.81% |
| Debt/Equity Ratio | 1.8% |
How did 300683 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 01:32 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Wuhan Hiteck Biological Pharma Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiaxi Xu | Industrial Securities Co. Ltd. |